Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate

Not Applicable

Terminated

• Conditions: Hypertension
• Interventions: Drug: Metoprolol; Drug: Nebivolol

• Registration Number: NCT00849810
• Lead Sponsor: University of Mississippi Medical Center

Brief Summary

The purpose of the study is to compare the effects of nebivolol and metoprolol on 24-hour ambulatory blood pressure characteristics and basal metabolic rates in patients with hypertension.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-01
• Study First Submitted: 2009-02-02
• Study First Submitted QC: 2009-02-23
• Study First Posted: 2009-02-24
• Primary Completion: 2010-11
• Study Completion: 2010-11
• Status Verified: 2013-03
• Results First Submitted: 2013-03-18
• Results First Submitted QC: 2013-03-18
• Last Update Submitted: 2013-03-18
• Results First Posted: 2013-03-19
• Last Update Posted: 2013-03-19

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• 18 years old or older
• currently be treated at a University of MS Medical Center Internal Medicine Clinics
• currently taking metoprolol succinate for hypertension
• have their hypertension controlled (<140/90).

Exclusion Criteria

• uncontrolled hypertension
• severe renal or moderate hepatic impairment
• currently taking CYP 2D6 inducers/inhibitors
• recent stroke (less than 6 months)
• recent myocardial infarction (less than 6 months)
• congestive heart failure
• diagnosed obstructive sleep apnea
• atrial fibrillation
• arm circumference >50 cm

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Metoprolol to nebivolol	Metoprolol	metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks.
Metoprolol to nebivolol	Nebivolol	metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks.

Primary Outcome Measures

Name	Time	Method
Primary Outcome is Pre- and Post-treatment Ambulatory Blood Pressure.	4 weeks (pre- and post-treatment)

Trial Locations

Locations (1)

University of Mississippi Medical Center; 🇺🇸 Jackson, Mississippi, United States